Drugs / vilamakitug
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05201352 | Oct 2022 → Oct 2026 expected | colorectal cancer | Centre Georges Francois Leclerc | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06526377 | Sep 2026 → Sep 2028 expected | ankylosing spondylitis | XBiotech, Inc. | Not yet recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT05099510 Comparator | Jan → May 2022 | — | XBiotech, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04825288 Comparator | May 2021 → Oct 2023 overdue | malignant pancreatic neoplasm | XBiotech, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | XBiotech, Inc. | Regulatory XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis xbiotech.com ↗
The study is now authorized to proceed with patient enrollment in the United States, marking the resumption of XBiotech’s rheumatology program. |
| 2021-04-19 | XBiotech, Inc. | Regulatory FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer xbiotech.com ↗
XBiotech (NASDAQ: XBIT) announced today that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | XBiotech, Inc. | XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis xbiotech.com ↗ |
| 2021-06-23 | XBiotech, Inc. | XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer xbiotech.com ↗ |
| 2021-04-19 | XBiotech, Inc. | FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer xbiotech.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vilamakitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06526377 ↗ |
| Known as | NatrunixTM | “The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha).” NCT05099510 ↗ |
| Known as | XB2001 | “The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha).” NCT05099510 ↗ |
| Action | Inhibit | “blocks the biological activity of IL-1α” NCT04825288 ↗ |
| Modality | Monoclonal antibody | “XB2001 is a True Human monoclonal antibody” NCT04825288 ↗ |
| Route | Intravenous | “XB2001 MTD as an intravenous infusion over up to 60 minutes” NCT04825288 ↗ |
| Target | IL1A | “specific for human interleukin-1-alpha (IL-1-alpha)” NCT05099510 ↗ |